The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
One partner. Every phase. Visit booth 6A2 at CPHI Milan 2026 to streamline drug development.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Taking An Informed Approach To Technology Selection To Address Solubility Challenges In Early Development
Webinar On Demand
As the need for more targeted drug therapies has increased and drug development has become more complex, the industry has seen a corresponding rise in the number of molecules with low solubility challenges. In fact, up to 90% of today’s drug candidates are plagued with low solubility. In light of this challenge, drug formulators must look to new techniques and formulation technologies to proactively address low solubility challenges and ensure effective treatments are reaching patients in need.
Topics covered in webinar:
- Challenges in early development posed by poorly soluble APIs
- Predictive modeling and analytic techniques to drive effective and efficient technology selection
- Amorphous dispersion and lipid formulation solutions to increase bioavailability
- Advantages to addressing low solubility in early development rather than waiting to address after initial clinical results
- Case studies
Authors:
Jon Sutch, Ph.D, Senor Manager of Formulation Development, Patheon
Christopher M. Lindemann, President, Focus Pharmaceutics, LLC